Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia

International Journal of Hematology

Volumn 81, Issue 3, 2005, Pages 242-245

  Ito, Katsuro ^a,b   Tominaga, Kazunori ^a   Suzuki, Toshiya ^a   Jinnai, Itsuro ^a   Bessho, Masami ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

AML; Imatinib mesylate; Minor BCR ABL

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CYTOGENETICS; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; MALE; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; RARE DISEASE; MIDDLE AGED; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 20344366536     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04098     Document Type: Article

References (17)

1. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
2. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
5. Savage DG, Antman KH. Imatinib mesylate: a new oral target therapy. N Engl J Med. 2002;346:683-693.
6. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
7. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study. Blood. 1992;80:2983-2990.
8. Paietta E, Racevskis J, Bennett JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia. 1998;12:1881-1885.
9. Katsuno M, Yamashita S, Sadamura S, et al. Late-appearing Philadelphia chromosome in a patient with acute nonlymphocytic leukaemia derived from myelodysplastic syndrome: detection of P210- and P190-type bcr/abl fusion gene transcripts at the leukaemic stage. Br J Haematol. 1994;87:51-56.
10. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol. 1989;9:1866-1874.
11. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
12. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blastic crisis: results of a phase II study. Blood. 2002;99:3530-3539.
13. Yamaguguchi M, Konishi I. Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia. Jpn J Clin Hematol. 2003;44:254-256.
14. Viniou N-A, Vassilakopoulos TP, Giakoumi X, et al. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1(+) acute myeloid leukemia. Eur J Haematol. 2004;72:58-60.
15. Scappini B, Onida F, Kantarjian HM, et al. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res. 2001;7:3884-3893.
16. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
17. Ottomann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-1971.